Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney | Zendy

Morie A. Gertz | Zendy; Nelson Leung | Zendy; M. Q. Lacy | Zendy; Angela Dispenzieri | Zendy; Steven R. Zeldenrust | Zendy; S. R. Hayman | Zendy; Francis K. Buadi | Zendy; D. Dingli | Zendy; Philip R. Greipp | Zendy; Shaji Kumar | Zendy; John A. Lust | Zendy; S. Vincent Rajkumar | Zendy; Stephen J. Russell | Zendy; T. E. Witzig | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney

Author(s) -

Morie A. Gertz,

Nelson Leung,

M. Q. Lacy,

Angela Dispenzieri,

Steven R. Zeldenrust,

S. R. Hayman,

Francis K. Buadi,

D. Dingli,

Philip R. Greipp,

Shaji Kumar,

John A. Lust,

S. Vincent Rajkumar,

Stephen J. Russell,

T. E. Witzig

Publication year - 2009

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfp201

Subject(s) - medicine , renal replacement therapy , creatinine , dialysis , amyloidosis , renal function , immunoglobulin light chain , kidney disease , kidney , hemodialysis , cohort , urology , gastroenterology , antibody , immunology

The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research